The present invention relates to a novel quercetin derivative compound and to a use thereof. More specifically, the present invention relates to a novel quercetin derivative compound having inhibitory activity against bromodomain extra-terminal (BET) proteins, and to a pharmaceutical composition for preventing or treating BET protein-related diseases, comprising the same.

The present invention relates to a novel quercetin derivative compound and to a use thereof. More specifically, the present invention relates to a novel quercetin derivative compound having inhibitory activity against bromodomain extra-terminal (BET) proteins, and to a pharmaceutical composition for preventing or treating BET protein-related diseases, comprising the same.

The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

The compound represented by formula (I), and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof have ROCK inhibitory activity. The compound represented by formula (1) has good safety, good metabolic stability, and a low risk of potential hepatotoxicity. Further, the compound represented by formula (I) has a simple preparation method and is easy to purify, and therefore has good application prospects.

##STR00001##

The compound represented by formula (I), and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof have ROCK inhibitory activity. The compound represented by formula (1) has good safety, good metabolic stability, and a low risk of potential hepatotoxicity. Further, the compound represented by formula (I) has a simple preparation method and is easy to purify, and therefore has good application prospects.

##STR00001##

Provided herein are indole compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease

Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: ##STR00001##
or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.

An organic EL device is provided, including at least an anode, a hole transport layer, a light-emitting layer, an electron transport layer, and a cathode in this order, wherein the hole transport layer contains an arylamine compound represented by the following formula (1), wherein Ar.sub.1 to Ar.sub.8 and n1 are defined in the specification, and the electron transport layer contains a compound having a benzoazole ring structure represented by the following formula (2), wherein Ar.sub.9, Ar.sub.10, X, Y.sub.1, Z.sub.1 and Z.sub.2 are defined in the specification. ##STR00001## ##STR00002##

An organic EL device is provided, including at least an anode, a hole transport layer, a light-emitting layer, an electron transport layer, and a cathode in this order, wherein the hole transport layer contains an arylamine compound represented by the following formula (1), wherein Ar.sub.1 to Ar.sub.8 and n1 are defined in the specification, and the electron transport layer contains a compound having a benzoazole ring structure represented by the following formula (2), wherein Ar.sub.9, Ar.sub.10, X, Y.sub.1, Z.sub.1 and Z.sub.2 are defined in the specification. ##STR00001## ##STR00002##